Neil Bhola, PhD

TitleAssistant Professor
SchoolUCSF School of Medicine
Address550 16th. Street
San Francisco CA 94158
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Brand TM, Hartmann S, Bhola N, Li H, Zang Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer. Cancer Res. 2018 Feb 12. PMID: 29440171.
      View in: PubMed
    2. Formisano L, Stauffer KM, Young CD, Bhola N, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL. Association of FGFR1 with ERa Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clin Cancer Res. 2017 Oct 15; 23(20):6138-6150. PMID: 28751448.
      View in: PubMed
    3. Jansen VM, Bhola N, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res. 2017 05 01; 77(9):2488-2499. PMID: 28249908.
      View in: PubMed
    4. Brand TM, Hartmann S, Bhola N, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RC, Johnson DE, Grandis JR. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2017 Jun 15; 23(12):3072-3083. PMID: 27986750.
      View in: PubMed
    5. Bhola N, Johnson DE, Grandis JR. A sensible approach to targeting STAT3-mediated transcription. Ann Transl Med. 2016 Oct; 4(Suppl 1):S57. PMID: 27868025.
      View in: PubMed
    6. Hartmann S, Bhola N, Grandis JR. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clin Cancer Res. 2016 Aug 15; 22(16):4005-13. PMID: 27370607.
      View in: PubMed
    7. Bhola N, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Res. 2016 Jan 15; 76(2):440-52. PMID: 26676751; PMCID: PMC4715956 [Available on 01/15/17].
    8. Bhola N, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res. 2015 Jan 15; 75(2):405-14. PMID: 25480943; PMCID: PMC4297507.
    9. Balko JM, Schwarz LJ, Bhola N, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 2013 Oct 15; 73(20):6346-58. PMID: 23966295; PMCID: PMC4090144.
    10. Bhola N, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-ß inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013 Mar; 123(3):1348-58. PMID: 23391723; PMCID: PMC3582135.
    11. Chakrabarty A, Bhola N, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013 Feb 01; 73(3):1190-200. PMID: 23204226; PMCID: PMC3563941.
    12. Bhola N, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Mol Cancer Ther. 2012 Jun; 11(6):1236-46. PMID: 22491800; PMCID: PMC3413198.
    13. Bhola N, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clin Cancer Res. 2011 Aug 01; 17(15):4996-5004. PMID: 21653688; PMCID: PMC3149755.
    14. Yang W, Cai Q, Lui VW, Everley PA, Kim J, Bhola N, Quesnelle KM, Zetter BR, Steen H, Freeman MR, Grandis JR. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J Proteome Res. 2010 Jun 04; 9(6):3073-82. PMID: 20426488; PMCID: PMC3149825.
    15. Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola N, Neill DB, Arbiser JL, Grandis JR. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010 May 01; 16(9):2571-9. PMID: 20388852; PMCID: PMC2871379.
    16. Qi Y, Dhiman HK, Bhola N, Budyak I, Kar S, Man D, Dutta A, Tirupula K, Carr BI, Grandis J, Bar-Joseph Z, Klein-Seetharaman J. Systematic prediction of human membrane receptor interactions. Proteomics. 2009 Dec; 9(23):5243-55. PMID: 19798668; PMCID: PMC3076061.
    17. Zhang W, Bhola N, Kalyankrishna S, Gooding W, Hunt J, Seethala R, Grandis JR, Siegfried JM. Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol Cancer Res. 2008 Dec; 6(12):1946-56. PMID: 19074839; PMCID: PMC3575100.
    18. Bhola N, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci. 2008 Jan 01; 13:1857-65. PMID: 17981673.
      View in: PubMed
    19. Zhang Q, Bhola N, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther. 2007 Apr; 6(4):1414-24. PMID: 17431120.
      View in: PubMed
    20. Thomas SM, Bhola N, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res. 2006 Dec 15; 66(24):11831-9. PMID: 17178880.
      View in: PubMed
    Back to TOP